AstraZeneca PLC (AZN) News
Track canonical SquawkNews coverage tagged to AZN, AstraZeneca PLC. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 145 indexed stories across 35 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
AstraZeneca-Daiichi breast-cancer drug Enhertu approved for routine use in England
NICE approved Enhertu for routine use in England after changing its recommendation following the U.S.-U.K. pharmaceutical-pricing deal.
REGULATION | Sep 17, 2026, 06:08 AM UTC
M
AstraZeneca shares jump after J.P. Morgan reiterates Overweight
AZN rose about 2.16% intraday after J.P. Morgan reiterated an Overweight rating, citing six Phase III readouts due in 2027 with more than $10 billion in risk-adjusted peak sales.
EQUITY | Sep 16, 2026, 07:11 PM UTC
H
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL ) received a bullish initiation from William Blair, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib. William Blair analys
LIVE | Sep 16, 2026, 05:38 PM UTC
M
Legend Biotech appoints Novartis veteran Ingrid Zhang as CEO
Legend Biotech (NASDAQ:LEGN) appointed longtime Novartis executive Ingrid Zhang as CEO, effective immediately.
EQUITY | Sep 15, 2026, 08:22 PM UTC
L
Broker tips: GSK, Astrazeneca, Vodafone
Berenberg said GSK's evolution was "undervalued", noting that 10 of its 11 novel phase—III assets had been sourced externally under new chief executive Luke Miels. It argued that six late—stage programmes each carried po
NEWS | Sep 15, 2026, 03:08 PM UTC
L
REG - AstraZeneca PLC - Director/PDMR Shareholding
RNS Number: 8206U AstraZeneca PLC 15 September 2026 15 September 2026Transaction by Person Discharging Managerial ResponsibilitiesAstraZeneca PLC (the Company) announces that it was notified on 14 September 2026 that Mic
NEWS | Sep 15, 2026, 02:00 PM UTC
L
Deutsche Bank upgrades Astrazeneca to 'hold'
The broker noted that the stock has fallen around 3% in absolute terms since its downgrade last October and lagged the sector by roughly 10% on an FX—adjusted basis.It said part of the weakness reflected factors it had a
EQUITY | Sep 15, 2026, 01:16 PM UTC
L
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech NASDAQ:LEGN on Tuesday appointed longtime Novartis BX:NOT executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy C
NEWS | Sep 15, 2026, 12:43 PM UTC
H
AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’
On CNBC’s “ Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked AstraZeneca PLC (NYSE: AZN ), Last week, Cambridge, U.K.-based AstraZeneca secured regulatory appro
LIVE | Sep 15, 2026, 11:39 AM UTC
L
AstraZeneca's Portfolio Diversity Bodes Well — Market Talk
AstraZeneca has a robust and diverse portfolio, with strong opportunities in its pipeline, analysts at Berenberg say in a note. The pharmaceutical company is on track to deliver 13% return on research and development inv
NEWS | Sep 15, 2026, 10:08 AM UTC
L
dpa-AFX Overview: Analyst recommendations on U.K. stocks
FRANKFURT (dpa-AFX) - The following investment banks issued recommendationson U.K. stocks this morning as follows:Analyst recommendations in the dpa-AFX International ProFeed on 15.09.2026 -11.00 am- BARCLAYS RAISES GREE
NEWS | Sep 15, 2026, 09:18 AM UTC
L
Enhertu Shows Six-Month PFS Gain In HER2-Mutant Lung Cancer
AstraZeneca and Daiichi Sankyo’s Enhertu reduced disease progression risk by 37% compared with pembrolizumab plus chemotherapy in a Phase III trialAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) demonst
NEWS | Sep 15, 2026, 08:33 AM UTC
L
AstraZeneca Target Raised to GBP117.00 From GBP115.00 by Deutsche Bank
AstraZeneca Target Raised to GBP117.00 From GBP115.00 by Deutsche Bank
NEWS | Sep 15, 2026, 06:31 AM UTC
L
AstraZeneca Raised to Hold From Sell by Deutsche Bank
AstraZeneca Raised to Hold From Sell by Deutsche Bank
NEWS | Sep 15, 2026, 06:31 AM UTC
L
REG - AstraZeneca PLC - Update on SERENA-4 Phase III trial
RNS Number: 5166U AstraZeneca PLC 14 September 2026 This announcement contains inside information14 September 2026Update on SERENA-4 Phase III trial of Etcamah in combination withpalbociclib in upfront 1st-line advanced
NEWS | Sep 14, 2026, 06:00 AM UTC
L
AstraZeneca's Breast-Cancer Trial Disappointment Doesn't Surprise — Market Talk
AstraZeneca's new breast-cancer drug Etcamah failed a late-stage clinical trial, but this was largely anticipated and might trigger a muted market reaction, J.P. Morgan analysts say in a research note. While disappointin
NEWS | Sep 14, 2026, 05:49 AM UTC
L
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
By Adria CalatayudAstraZeneca said its new breast-cancer pill missed the key goal of slowing the disease from worsening in a late-stage clinical trial.The U.K. drugmaker evaluated its Etcamah medicine, in combination wit
NEWS | Sep 14, 2026, 05:33 AM UTC
L
Weekly Recap: Tozorakimab cuts COPD events and ENHERTU improves PFS
AstraZeneca PLC (LSE:AZN) reported mixed clinical news: robust positive Phase 3 and Phase 2 results across COPD (tozorakimab), HER2—mutant NSCLC (ENHERTU), TAGRISSO long—term survival and Imfinzi+tarlatamab, alongside a
NEWS | Sep 14, 2026, 05:15 AM UTC
L
AstraZeneca Says Enhertu Demonstrates 14.3 Month Median Progression-Free Survival In Destiny-Lung04 Phase III Trial
AstraZeneca PLC LSE:AZN
NEWS | Sep 14, 2026, 02:33 AM UTC
L
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement i
NEWS | Sep 14, 2026, 01:55 AM UTC
L
AstraZeneca Says Tagrisso® (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial
AstraZeneca PLC LSE:AZN
NEWS | Sep 14, 2026, 01:49 AM UTC
L
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in
NEWS | Sep 14, 2026, 01:47 AM UTC
L
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Positive results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus glo
NEWS | Sep 14, 2026, 01:45 AM UTC
L
Olema drops after hours on AstraZeneca Etcamah data
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
NEWS | Sep 11, 2026, 10:33 PM UTC
L
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
Shares of AstraZeneca traded 3% lower in after-hours trading on Friday after the drugmaker said a large late-stage breast cancer study of Etcamah missed its main goal, denting hopes of a broader first-line use for one of
EQUITY | Sep 11, 2026, 10:11 PM UTC
L
AstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
NEWS | Sep 11, 2026, 10:11 PM UTC
L
AstraZeneca's breast cancer drug fails in late-stage trial
AstraZeneca's LSE:AZN breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently approved treatment.U.S.-listed
EQUITY | Sep 11, 2026, 08:45 PM UTC
L
AstraZeneca Says SERENA-4 Phase III Trial Of Etcamah With Palbociclib Does Not Meet Primary Endpoint
AstraZeneca PLC LSE:AZN
NEWS | Sep 11, 2026, 08:41 PM UTC
L
Astrazeneca's breast cancer drug fails late-stage trial
AstraZeneca LSE:AZN said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
NEWS | Sep 11, 2026, 08:26 PM UTC
L
AstraZeneca shares fall about 1.3% after positive Phase 3 COPD results
AstraZeneca fell about 1.3% to $158 Wednesday, after its experimental COPD treatment reported positive Phase 3 results.
EQUITY | Sep 09, 2026, 06:02 PM UTC
H
UK stocks slide to over-one-month low as oil tops $100
London’s FTSE indexes fell in a broad selloff on Wednesday. The FTSE 100 slipped 1.31% to 10,670.06 points at close after oil moved above $100 a barrel amid Middle East conflict-related inflation worries.
COMMODITIES | Sep 09, 2026, 04:11 PM UTC
L
RBC starts EU pharma coverage with Outperform ratings for AstraZeneca, Roche
RBC Capital Markets launched EU pharma coverage: Outperform for AstraZeneca and Roche, and Sector Perform for Sanofi, Novartis and GSK.
EQUITY | Sep 09, 2026, 02:43 PM UTC
L
AstraZeneca Shares Look Set for Swift Recovery — Market Talk
AstraZeneca shares have been overly punished by recent concerns, but they look set for a swift recovery once uncertainty dissipates, RBC Capital Markets analysts say in a research note. The failure of a heart-disease cli
MNA | Sep 09, 2026, 02:01 PM UTC
H
Cramer favors Nucor and likes Simon and Federal Realty
Jim Cramer said he would not back AstraZeneca or Joby Aviation, citing missing trials and losses. He also backed Nucor, and said Simon Property Group and Federal Realty are “excellent.”
EARNINGS | Sep 09, 2026, 12:56 PM UTC
L
AstraZeneca COPD drug data lifts Citi sales outlook sharply
Citi analysts say AstraZeneca’s blowout clinical data for tozorakimab supports sales expectations sharply above current consensus estimates, according to a research note.
EARNINGS | Sep 09, 2026, 12:29 PM UTC
L
AstraZeneca target set at GBP145 by RBC
RBC started coverage on AstraZeneca with a GBP145 target.
EQUITY | Sep 09, 2026, 06:23 AM UTC
L
AstraZeneca started at Outperform by RBC
AstraZeneca was started at Outperform by RBC.
EQUITY | Sep 09, 2026, 06:23 AM UTC
M
Amgen-AstraZeneca Imdelltra plus Imfinzi improves survival in SCLC trial
Amgen said its Imdelltra targeted immunotherapy with AstraZeneca’s Imfinzi significantly improved overall survival in extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday.
EQUITY | Sep 08, 2026, 08:26 PM UTC
H
Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials
By Nancy LapidHello Health Rounds readers! Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.Experimental drug reduces lung-disease flaresA drug being de
GEOPOLITICS | Sep 08, 2026, 06:47 PM UTC
M
AzN’s tozorakimab shows broad COPD efficacy; FDA priority review
Tozorakimab demonstrated significant reductions in COPD exacerbations across patient subgroups. The program has FDA priority review and is projected to peak sales exceeding $5 billion.
REGULATION | Sep 08, 2026, 06:20 PM UTC
L
Tozoracimab shows COPD exacerbation cuts across subgroups
Tozoracimab demonstrated reduced COPD exacerbations across patient subgroups, including those with low eosinophil counts. The therapy received FDA priority review and a potential launch in Q1 2027, with expected peak sal
EARNINGS | Sep 08, 2026, 04:41 PM UTC
M
AstraZeneca shares fall despite Imfinzi survival-test win
AstraZeneca’s U.S. shares (AZN) fell about 0.7% to $161.51 even after Imfinzi, with Amgen’s Imdelltra, significantly extended survival among patients in a late-stage lung-cancer study.
EQUITY | Sep 08, 2026, 04:36 PM UTC
L
AstraZeneca’s tozorakimab shows up to 34% fewer COPD exacerbations
A Phase III trial found tozorakimab reduced COPD exacerbations by up to 34% across eosinophil levels, with safety comparable to placebo. AstraZeneca links its respiratory & immunology portfolio to 2030 growth targets.
EARNINGS | Sep 08, 2026, 04:29 PM UTC
M
AstraZeneca reports positive Phase III lung cancer trial results
AstraZeneca’s DeLLphi-305 Phase III trial says a combination of Imfinzi with Amgen’s Imdelltra produced statistically significant, clinically meaningful overall survival improvement in ES-SCLC patients.
EQUITY | Sep 08, 2026, 02:54 PM UTC
M
AstraZeneca says Imfinzi and Imdelltra improved survival
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival for extensive-stage small-cell lung cancer patients in a late-stage trial.
EQUITY | Sep 08, 2026, 01:51 PM UTC
M
AstraZeneca/Amgen Imfinzi–Imdelltra combo improves survival goal
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial, meeting its main survival goal.
EQUITY | Sep 08, 2026, 01:14 PM UTC
L
AstraZeneca COPD drug tozorakimab shows benefits across patient groups
AstraZeneca said tozorakimab for chronic obstructive pulmonary disease showed benefits across a broad patient population in late-stage clinical trials, supporting its expectation of multibillion-dollar sales.
EARNINGS | Sep 08, 2026, 01:04 PM UTC
M
IMFINZI plus tarlatamab interim DeLLphi-305 data show OS and PFS gains
Planned interim analysis of DeLLphi-305 Phase III showed IMFINZI (durvalumab) plus tarlatamab delivered statistically significant improvement in overall survival versus IMFINZI alone in 1st-line extensive-stage small cel
EQUITY | Sep 08, 2026, 01:01 PM UTC
M
AstraZeneca says Imfinzi plus Imdelltra improved survival in SCLC
AstraZeneca PLC said Imfinzi plus Imdelltra showed statistically significant and highly clinically meaningful improvements in overall survival and progression-free survival in 1st-line extensive-stage small cell lung can
EQUITY | Sep 08, 2026, 01:00 PM UTC
L
Yomiuri flags U.S. drug pricing policy risks for Japan supply
Yomiuri reports a U.S. drug pricing policy linked to President Donald Trump is raising fears Japan’s “drug-loss” problem could worsen, with medicines used overseas becoming unavailable domestically.
EQUITY | Sep 08, 2026, 12:13 PM UTC
M
Barclays trims AstraZeneca and GSK targets on U.K. stock notes
In analyst action on U.K. stocks, Barclays cut AstraZeneca’s price target to 16000 pence from 16500, keeping an Overweight stance. Barclays also cut GSK’s target, with more details truncated in the feed.
EQUITY | Sep 08, 2026, 09:19 AM UTC
L
AstraZeneca FDA approval for breast-cancer drug supports sentiment
Citi says AstraZeneca’s U.S. Food and Drug Administration approval for breast-cancer drug Etcamah may matter more for investor sentiment than near-term revenue. The approval points to a relatively modest opportunity vers
REGULATION | Sep 07, 2026, 02:36 PM UTC
M
AstraZeneca gets US accelerated approval for breast cancer drug
AstraZeneca said its breast cancer drug received FDA accelerated approval, based on an FDA-authorised blood test detecting emerging ESR1 mutations tied to reduced effectiveness of current treatment. The decision follows
REGULATION | Sep 07, 2026, 07:50 AM UTC
M
AstraZeneca says Etcamah approved in US for HR+ breast cancer
AstraZeneca said Etcamah was approved in the US for HR+ breast cancer.
EQUITY | Sep 07, 2026, 07:01 AM UTC
M
AstraZeneca’s Etcamah gets accelerated US approval for advanced breast cancer
AstraZeneca said its breast cancer drug Etcamah (camizestrant), used with a CDK4/6 inhibitor, received accelerated approval in the US for patients with a common form of advanced breast cancer showing resistance signs.
MNA | Sep 07, 2026, 06:43 AM UTC
L
AstraZeneca U.S. regulator approval for breast-cancer drug Etcamah
U.S. regulators approved AstraZeneca’s breast-cancer drug Etcamah for use in combination with therapies including Pfizer’s Ibrance and Eli Lilly’s Verzenio, in a development analysts at J.P. Morgan called a minor positiv
EQUITY | Sep 07, 2026, 06:02 AM UTC
M
AstraZeneca’s Etcamah approved in the US for HR+ breast cancer
AstraZeneca PLC said Etcamah in combination with a CDK4/6 inhibitor has been approved in the US for 1st-line advanced HR-positive breast cancer. Approval is based on SERENA-6 Phase III trial results.
EQUITY | Sep 07, 2026, 06:00 AM UTC
M
AstraZeneca’s ETCAMAH (camizestrant) combo gains US 1st-line HR+ breast cancer approval
AstraZeneca says ETCAMAH (camizestrant) with a CDK4/6 inhibitor—abemaciclib, palbociclib or ribociclib—has been approved in the US for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast
EQUITY | Sep 04, 2026, 11:03 PM UTC
M
FDA grants accelerated approval for AstraZeneca breast cancer treatment
The Food and Drug Administration granted accelerated approval for AstraZeneca’s Etcamah (camizestrant) in combination with a CDK4/6 inhibitor to treat eligible advanced breast cancer patients.
REGULATION | Sep 04, 2026, 10:33 PM UTC
M
AZN receives accelerated approval for breast cancer treatment
AZN says the FDA has granted accelerated approval for a new breast cancer treatment.
REGULATION | Sep 04, 2026, 07:53 PM UTC